Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 24, 2005. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the registrant.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of shareholding changes rather than a financial performance report.
Material Changes
The filing details a change in the holdings of the GlaxoSmithKline US Retirement Savings Plan ("the Plan") resulting from a fund movement on October 20, 2005:
- Previous Holding: 18,313,302 Ordinary Share ADRs
- New Holding: 18,292,670 Ordinary Share ADRs
- Average Price: $50.46
- Net Change: Decrease of 20,632 ADRs
Two directors, Dr. J P Garnier and Dr. T Yamada, are noted as potentially interested in the shares held in the fund in the same capacity as other employees.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document strictly addresses compliance with Disclosure Rule 3.1.4R(1)(b) regarding the notification of the transaction.
Key Facts for Investor Verification
- Verify the impact of the 20,632 ADR reduction on the total share count of the US Retirement Savings Plan.
- Confirm the specific nature of the "fund movement" that triggered the change in holdings.
- Review the broader context of director shareholdings to ensure full compliance with disclosure rules.